Atlas Trials

Camrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction Adenocarcinoma

Clinical trial NCT06163729 · RECRUITING

Trial details

NCT number
NCT06163729
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Gastroesophageal Junction Adenocarcinoma (Siewert II-III)
Start date
2022-08-25
Primary completion
2025-05-01
Enrollment
68

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.